Sponsors are developing increasingly complex therapeutics that require expertise across multiple bioanalytical platforms. Through a strategic collaboration, Sword Bio and Alturas Analytics provide biotechnology and pharmaceutical companies with coordinated access to complementary bioanalytical capabilities across large- and small-molecule drug development.
The collaboration brings together Sword Bio’s expertise in ligand-binding assays, including pharmacokinetic (PK), immunogenicity and biomarker applications, with Alturas Analytics’ expertise in mass spectrometry-based bioanalysis supporting preclinical and clinical research. Together, Sword Bio and Alturas Analytics provide sponsors with access to specialized scientific teams and technologies through a coordinated framework—helping simplify complex bioanalytical programs while maintaining the responsiveness, flexibility and direct scientific communication associated with specialized CROs.
"*" indicates required fields
The collaboration is particularly well suited for programs requiring multiple analytical strategies and technologies, including antibody-drug conjugates (ADCs).
ADC development can require coordinated bioanalytical strategies to characterize multiple components of these complex therapeutics. Through the collaboration, sponsors can access Alturas Analytics’ mass spectrometry-based bioanalytical capabilities and noncompartmental analysis (NCA), together with Sword Bio’s ligand-binding and immunogenicity expertise, including anti-drug antibody (ADA) assessment.
The result is a more coordinated approach to generating and interpreting bioanalytical data—while preserving the specialized scientific expertise, responsiveness and direct communication sponsors expect from both organizations.
Alturas Analytics is a regulated bioanalytical CRO specializing in LC-MS/MS solutions for drug discovery and development. Since 2000, Alturas has provided bioanalytical services for preclinical and clinical research, generating high-quality data to support drug development programs from early-stage research through clinical development and regulatory submissions.
In addition to providing PK support services, including noncompartmental analysis (NCA), to pharmaceutical and biotechnology companies worldwide, Alturas maintains an intensive research effort focused on applying new technologies and analytical approaches to advance bioanalytical science. The company’s success is built on developing long-term client relationships by combining scientific expertise with high-quality bioanalytical results, responsive service and timely execution.
Sword Bio is a bioanalytical contract research organization that partners with biotechnology and pharmaceutical companies to deliver data essential to their drug development needs. Sword Bio’s team of experienced scientists provides assay development, validation and sample analysis under regulated and non-regulated conditions, supporting PK, immunogenicity and biomarker assays for preclinical and clinical studies.
Sword Bio combines scientific expertise with a highly collaborative approach focused on high-quality science, data integrity, regulatory compliance, responsiveness and on-time execution. By starting projects quickly and maintaining close communication throughout each engagement, Sword Bio helps clients efficiently advance their drug development programs.
Dr. Jennifer Zimmer is the Chief Operating Officer at Alturas Analytics, Inc. and has worked in the field of bioanalysis for over 20 years. Dr. Zimmer is responsible for the overall operation of the Alturas Analytics laboratory, ensuring client deliverables are met while working laterally with Alturas QAU to maintain laboratory compliance with all procedures and regulations.
"*" indicates required fields